RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 No Significant Difference in Treatment versus Supportive Care in Stage IV NSCLC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 3
SP 10
OP 11
DO 10.1177/155989771403005
UL http://mdc.sagepub.com/content/14/3/10.abstract
AB Researchers in Egypt conducting a prospective, Phase 3, randomized trial found no significant difference in time to progression or overall survival in patients with stage IV advanced and metastatic non—small cell lung cancer (NSCLC) who received either gemcitabine or best supportive care after induction therapy. Findings were displayed in a poster presentation.